Skip to content

Study · Not a test of the peptide alone · 2021

3 results

Increased Serum High-Sensitivity C-Reactive Protein in Growth Hormone-Deficient Patients With Non-Functioning Pituitary Tumors

Seki Y, Ichihara A

Journal of the Endocrine Society3 May 2021

PMCIDPMC8090618 (opens in a new tab)PepBankPUB-99181795
Read at sourceSource pageAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-2.

  1. 01HumanNot a test of GHRP-2 aloneObservational studyOther

    In 81 adults with non-functioning pituitary adenoma or Rathke's cyst, 44% were diagnosed with severe GH deficiency by the GHRP‑2 test.

    In plain wordsIn 81 adults with pituitary tumours, 44% had severe growth hormone deficiency on a GHRP‑2 test. This is a diagnostic result.

    Peptide
    GHRP-2
    Outcome
    Not applicableSevere GH deficiency by GHRP-2 test
    Study

    n = 81

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Of 81 patients (70 NFPA and 11 Rathke’s cyst), 44% were diagnosed as severe GH deficiency by GHRP-2 test.
    1 context sentence
    Summary · context
    In this retrospective study, adult patients with non-functioning pituitary adenoma (NFPA) and Rathke’s cyst who received a GH-releasing pepitide-2 (GHRP-2) test from 2013 until 2016 were included.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  2. 02HumanNot a test of GHRP-2 aloneObservational studyOther

    In adults with non-functioning pituitary tumours, serum hs-CRP correlated inversely with the peak GH response to the GHRP‑2 test (r = -0.48).

    In plain wordsIn adults with pituitary tumours, higher hs-CRP was linked to a lower peak growth hormone response on a GHRP‑2 test.

    Peptide
    GHRP-2
    Outcome
    Not applicableCorrelation of hs-CRP with peak GH response to GHRP-2
    Study

    n = 81

    Outcome group
    Inflammation markers · Endocrine and hormones

    Measurements

    Correlation r
    −0.48 r
    hs-CRP vs peak GH response to GHRP-2

    Source sentences

    Summary
    peak GH response to GHRP-2 (r = -0.48, P < 0.001), AST (r = 0.32, P = 0.004), ALT (r = 0.34, P = 0.002), γGTP (r = 0.41, P < 0.001), HDL-cholesterol (r = -0.33, P = 0.003) and triglyceride (r = 0.25, P = 0.02).
    1 context sentence
    Summary · context
    In this retrospective study, adult patients with non-functioning pituitary adenoma (NFPA) and Rathke’s cyst who received a GH-releasing pepitide-2 (GHRP-2) test from 2013 until 2016 were included.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

  3. 03HumanNot a test of GHRP-2 aloneObservational studyOther

    After adjustment for age, sex, BMI and other variables, the peak GH response to GHRP‑2 remained a significant determinant of serum hs-CRP (beta = -0.24).

    In plain wordsAfter adjustment, a lower peak growth hormone response on a GHRP‑2 test stayed linked to higher hs-CRP.

    Peptide
    GHRP-2
    Outcome
    Not applicablePeak GH response to GHRP-2 as predictor of hs-CRP after adjustment
    Study

    n = 81

    Outcome group
    Inflammation markers · Endocrine and hormones

    Measurements

    Beta
    −0.24 beta
    peak GH response to GHRP-2 on hs-CRP

    Source sentences

    Summary
    Peak GH response to GHRP-2 (β = -0.24, P = 0.024) was a significant variable to determine serum hs-CRP level after adjustment for age, sex, BMI, regularly alcohol intake and serum creatinine, γGTP and HDL-cholesterol levels.
    1 context sentence
    Summary · context
    In this retrospective study, adult patients with non-functioning pituitary adenoma (NFPA) and Rathke’s cyst who received a GH-releasing pepitide-2 (GHRP-2) test from 2013 until 2016 were included.

    In this study, GHRP-2 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-2.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    13 Oct 2026, 21:44 UTC

    Study results updated

  2. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.